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Introduction
It is a widespread belief among anaesthesiologists that the spontaneous recovery of neuromuscular blocking agents (NMBA) may be sufficient to avoid postoperative residual paralysis (PORP), if enough time has passed since the last NMBA administration. In these cases, it is assumed that pharmacological reversal may not be necessary. However, the 
time course of spontaneous recovery is dependent on a multitude of factors; the duration for sufficient recovery of neu-
romuscular transmission is difficult to predict (1, 2). Understandably, the practice of relying only on the natural decay of 
Objective: Some anaesthetists are convinced that a long interval 
since the last relaxant dose may be sufficient to recover from anaes-
thesia without a pharmacological reversal. We intended to demon-
strate that the dosing pattern of rocuronium could not predict the 
necessity of reversal.
Methods: In a cohort analysis, we retrospectively analysed 180 an-
aesthesia records of adult patients who underwent elective surgical 
interventions in general anaesthesia and tracheal intubation with 
rocuronium-induced neuromuscular blockade. The extracted re-
cords were divided to 3 post hoc groups of 60 each, according to 
the reversal method employed at the end of anaesthesia: group N 
with neostigmine, group S with sugammadex and group Z without 
pharmacological reversal. All cases were terminated after achieving 
a train of four ratio of 0.9. Dosing patterns of rocuronium were 
compared by applying a novel pharmacometric calculation meth-
od, residual drug activity coefficient (RDAC), which employs both 
the administered individual drug doses in mg kg-1 and the timing 
of each drug administration in relation to the time of extubation. 
The rocuronium dosing pattern was correlated with the employed 
method of neuromuscular blockade reversal.
Results: The dosing for rocuronium in patients without pharma-
cological reversal was lower than that in both reversal agent groups 
(n=0.58±0.21, S=0.58±0.17 and Z=0.47±0.17), but there was still 
a large overlap in the RDAC.
Conclusion: The dosage profile of rocuronium alone cannot pre-
dict the possibility to refrain from pharmacological reversal.
Keywords: Neuromuscular blockade, extubation, rocuronium, re-
versal
Amaç: Bazı anestezi uzmanlarına göre, en son uygulanan nöro-
müsküler bloker dozundan itibaren geçen uzun bir aralık, farma-
kolojik bir geri dönüş olmaksızın, anesteziden sonra derlenme için 
yeterlidir. Bu çalışmada amaç rokurunyum dozaj şeklinin, geri 
dönüş gerekliliğini öngöremediğini göstermektir.
Yöntemler: Bu kohort çalışmada, genel anestezi altında elektif 
cerrahi müdahale ve rokuronyum ile indüklenen nöromusküler 
blokaj ile trakeal intübasyon uygulanan 180 yetişkin hastanın 
anestezi kayıtları retrospektif olarak değerlendirildi. Elde edilen 
kayıtlar, anestezi sonunda uygulanan geri dönüş yöntemine göre 
her biri 60 kişiden oluşan 3 post hoc gruba ayrıldı: neostigmin 
kullanılan Grup N, sugammadeks kullanılan Grup S ve farma-
kolojik geri dönüş kullanılmayan Grup Z. Tüm vakalar "train of 
four" oranı 0.9 elde edilince sonlandırıldı. Rokuronyumun doz 
paterni, yeni bir farmakometrik hesaplama metodu (rezidüel ilaç 
aktivite katsayısı) uygulanarak karşılaştırıldı. Bu katsayı mg kg-1 
olarak uygulanan bireysel ilaç dozlarını ve ekstübasyon zamanıyla 
ilişkili olarak her ilaç uygulama zamanlamasını kullanmaktadır. 
Rokuronyum dozaj şekli ile uygulanan nöromusküler blokaj geri 
dönüş yöntemi ile ilişkiliydi. 
Bulgular: Farmakolojik geri dönüş kullanılmayan hastalarda ro-
kuronyum dozajı, geri dönüş ajanı kullanılan diğer iki gruba göre 
daha düşüktü (n=0,58±0,21, S=0,58±0,17 ve Z=0,47±0,17). Ancak 
RDAC değerinde halen büyük bir örtüşüm (overlap) vardı. 
Sonuç: Tek başına rokuronyum dozaj profili farmakolojik geri dö-
nüşten kaçınma olasılığını öngöremez. 
Anahtar Kelimeler: Nöromusküler blokaj, ekstübasyon, ro-
kuronyum, geri dönüş
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NMBA cannot be substantiated by prospective investigations 
for ethical reasons. Instead, it is possible to retrospectively 
analyse rocuronium dosing patterns from electronically ar-
chived anaesthesia records with the aim to compare the do-
sing patterns of rocuronium and pharmacologic antagonists. 
All three different practices may be correct and acceptable, if, 
at the time of extubation, the neuromuscular transmission 
has recovered to a train of four (TOF) ratio of at least 0.9, 
which in turn must have been confirmed by quantitative 
relaxometry. In this investigation, we analysed anaesthetic 
records from cases in which rocuronium was antagonised 
with either neostigmine or sugammadex or in which rocuro-
nium was allowed to recover spontaneously without reversal. 
The time to reversal was compared in the context of dosing 
patterns over time while having arrived at a neuromuscular 
function of a TOF ratio of 0.9 (3-6).
Methods 
In a single-centre, retrospective study, we extracted data from 
archived electronic anaesthesia records in which rocuronium 
was used as the only NMBA for the entire surgical procedure, 
and at termination of anaesthesia, the TOF ratio has recove-
red to 0.9 either with or without a pharmacological reversal. 
The Cantonal Ethical Committee approved this investigation 
(No. 2016-01202, chaired by Peter Meier-Abt) necessitating 
that patient data should be de-identified to protect personal 
health information. Informed consent from the patients was 
not required. To obtain comparable groups with different re-
versal strategies for avoiding PORP and after performing a 
power analysis, we selected 180 of the most recent anaesthesia 
records that met our inclusion criteria and divided them to 
three post hoc study groups:
• Group N=reversal of rocuronium-induced neuro-
muscular block with neostigmine (n=60).
• Group S=reversal of rocuronium-induced neuro-
muscular block with sugammadex (n=60).
• Group Z=spontaneous recovery of rocuronium wi-
thout pharmacological reversal (n=60).
The investigated parameter was the underlying rocuronium 
dosage pattern expressed in a defined residual drug activity 
coefficient (RDAC) at end of anaesthesia (7). In a prelimi-
nary power analysis of the expected differences between the 
groups due to the duration of action variability of rocuro-
nium, a sample size of 180 was considered sufficient.
The inclusion criteria were general anaesthesia with tracheal 
intubation and neuromuscular relaxation with rocuronium in 
patients undergoing elective surgery, with a duration of anaes-
thesia >60 minutes. Exclusion criteria were the use of other 
muscle relaxants and sedative drugs, such as dehydrobenzpe-
ridol or clonidine, (8) and with neuromuscular diseases or 
other conditions that may affect neuromuscular function.
All the cases were performed as total intravenous anaesthesia 
with propofol for induction and maintenance of anaesthesia 
and analgesia with fentanyl/remifentanil combinations. All 
patients were extubated at the end of surgery as per usual cli-
nical routine, based on the anaesthetists’ clinical judgement. 
The termination of anaesthesia was permitted as soon as the 
return of neuromuscular transmission has arrived at 0.9 TOF 
ratio either with or without pharmacological reversal.
Determination of the individual residual drug activity 
coefficient (RDAC)
To compare dosing patterns of rocuronium, we used the 
RDAC method, which is a pharmacometric calculation 
method (7) employing both the administered repetitive in-
dividual drug doses (mg kg-1) and the timing of each drug 
administration in relation to a defined reference time. As re-
ference time for the RDAC calculations we used the time of 
extubation. RDAC is an ideal tool to describe drug amount 
and time related dosage patterns. In particular, it considers 
the fact that drug doses given closer to the reference time have 
a stronger residual effect, which indicates a more pronounced 
residual neuromuscular weakness compared to an identical 
total dose per body weight and time that has been administe-
red predominantly earlier during the same time frame.
The formula to calculate RDAC is as follows:
where D/m is a particular bolus dose in mg/kg and ΔT is the 
time difference between drug application and reference time 
in minutes. The numerals indicate consecutive bolus doses 
with 1 representing the first bolus, 2 representing the second 
bolus, on and so forth.
Data acquisition and analysis
The extracted records were divided into the 3 post hoc study 
groups N, S and Z with 60 cases each. The following demo-
graphic and clinical data were collected from de-identified 
patient records: 
• Patients’ age, gender, weight and height.
• Duration of anaesthesia.
• Rocuronium dosage profile (according to RDAC) 
(Biro 2013).
• Choice of reversal agents and their dosage or non-re-
versal.
Statistical analysis
The power analysis was based on an ANOVA-test using three 
groups, an a-error probe of 0.05, a power of 90%, and an esti-
mated effect size of 0.3, resulting in a total sample size of 180. 
The Chi-square test was used for analysis of nominal and ordinal 
data. For continuous data, normality was tested using the Sha-
piro-Wilk normality test. Normally distributed data were com-
pared by one-way ANOVA, not normally distributed data using 
Kruskal–Wallis test and multiple comparisons were corrected 
using the Tukey’s or Dunn’s multiple comparison tests, respec-
tively. A p value of <0.05 was considered statistically significant.
Turk J Anaesthesiol Reanim 2018; 46: 57-61
58
Power calculation was performed using G*Power 3.1 
(G*Power, Düsseldorf, Germany) and statistical analyses 
were calculated using GraphPad Prism (GraphPad Incorp, 
San Diego, CA).
Results
The 180 analysed cases originated from March to September 
2016 at the University Hospital Zurich. The assembled three 
post hoc groups of patient records from precedent anaesthe-
tics were comparable with regard to biometric data of the in-
volved patients (Table 1). A statistically significant difference 
was found in body weight, which however may be considered 
clinically irrelevant since the compared rocuronium doses 
were calculated on a mg kg-1 basis. There was also a slight 
difference in the anaesthesia duration between the neostig-
mine and sugammadex reversal groups (N vs. S) but not 
between these groups and the natural decay group (Z).
Neither the total individual doses of rocuronium nor the 
doses adjusted to body weight showed a significant difference 
in the 3 post hoc groups. However, when the timing context 
was included to describe the dosing pattern by comparing 
RDAC, a statistically significant difference to the natural de-
cay group (Z) was found (Table 2), albeit there was a large 
overlap of rocuronium dosing in all three groups (Figure 1). 
The RDAC for rocuronium in Group Z was on an average 
lower than that in both the reversal agent groups (which 
Table 1. Demographics and clinical data of the patients from the extracted anaesthesia records 
 Group N (n=60) Group S (n=60) Group Z (n=60) 
 Reversal with  Reversal with No reversal 
n=180 neostigmine  sugammadex  (natural decay) Statistical significance
Gender distribution 25M/35F 31M/29F 31M/29F N vs. S: n.s. 
    N vs. Z: n.s. 
    Z vs. S: n.s.
Age (years) 56±18 61±15 50±17 N vs. S: n.s. 
mean±SD    N vs. Z: n.s. 
    Z vs. S: n.s.
Height (cm) 168±9 169±8 172±9 N vs. S: n.s. 
mean±SD    N vs. Z: n.s. 
    Z vs. S: n.s.
Weight (kg) 70±18 83±22 78±22 N vs. S< 0.05 
mean±SD    N vs. Z: n.s. 
    Z vs. S: n.s.
Duration of 217±96 203±71 224±80 N vs. S< 0.05 
anaesthesia (min)    N vs. Z: n.s. 
mean±SD    Z vs. S: n.s.
n.s.: no statistically significant difference; M: male; F: female
Table 2. Rocuronium doses and dosing patterns 
 Group N (n=60) Group S (n=60) Group Z (n=60) 
 Reversal with  Reversal with No reversal 
n=180 neostigmine  sugammadex  (natural decay) Statistical significance
Total individual rocuronium 90±31 84±26 90±29 N vs. S: n.s. 
dose (mg)    N vs. Z: n.s. 
mean±SD    Z vs. S: n.s.
Rocuronium dose per body  1.3±0.4 1.05±0.31 1.18±0.33 N vs. S<0.05 
weight (mg kg-1)    N vs. Z: n.s. 
mean±SD    Z vs. S<0.05
Rocuronium dose per body weight  0.4±0.15 0.33±0.11 0.34±0.12 N vs. S: n.s. 
and anaesthesia duration (mg kg-1 h-1)    N vs. Z: n.s. 
mean±SD    Z vs. S: n.s.
Residual drug activity coefficient 0.58±0.21 0.58±0.17 0.47±0.17 N vs. S: n.s. 
mean±SD    N vs. Z<0.05 
    Z vs. S<0.05
n.s.: no statistically significant difference
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otherwise had the same RDAC). This indicates a tendency for 
the omission of pharmacological reversal if the rocuronium 
dosage profile was considered suitable for non-reversal by the 
involved anaesthetists, and a TOF ratio of 0.9 confirmed this 
circumstance.
Discussion
There are indications that PORP may be associated with pos-
toperative morbidity and mortality and therefore must care-
fully be avoided (4-6, 9). Hence, there is a generally accepted 
consensus that neuromuscular transmission should return to 
normal before the end of anaesthesia which can be confir-
med by a minimum TOF ratio of 0.9. This condition be-
came a standard operating procedure in our department. This 
threshold can only be recognized by monitoring the neuro-
muscular function objectively throughout the procedure. In 
routine clinical practice, we often hear the opinion of collea-
gues that if “a long enough time” has passed since the last 
administration of rocuronium (or another non-depolarizing 
neuromuscular blocking agent (NMBA), a sufficient neuro-
muscular recovery can be expected. However, those advoca-
ting this reliance on the spontaneous recovery of the relaxant 
cannot establish a safe time lag or time-related dosing pattern 
that would be indicative of a safe recovery from anaesthesia. 
Such an attitude has been repeatedly questioned by authors 
who have shown the large variability of the action duration 
of NMBA in clinical practice (10). In patients without pre-
vious reversal of NMBA, a prevailing PORP may be present, 
although the anaesthetist erroneously might believe that his/
her patient may be fit for unassisted spontaneous breathing 
via a safely protected airway. The tendency to adopt this prac-
tice might be reinforced by a clinician’s desire to avoid the un-
desirable side effects of reversal with the cholinesterase-bloc-
ker neostigmine and by economic considerations related to 
sugammadex.
With our investigation, we intended to determine whether there 
is a difference in the dosing pattern of rocuronium in the actual 
routine practice of our colleagues, which might help distinguish 
if reversal was necessary or could be omitted. The hereby-applied 
RDAC is the most appropriate pharmacometric parameter be-
cause it not only considered the repetitive rocuronium doses per 
body weight and the total duration of rocuronium administra-
tion, but also particularly displays the dosing/time-relationship 
towards the reference time of extubation. The RDAC values 
extracted from our study revealed a lower mean RDAC for the 
natural decay group (Z) at 0.47 compared to 0.58 for both re-
versal groups, indicating that there was a tendency to omit phar-
macological reversal in cases with a longer time duration since 
the relaxant was given. However, this difference is insufficient 
for a clear distinction because there is still a large mutual over-
lap of standard deviations between the RDAC values of the 3 
groups, thus blurring an eventual threshold. Only an RDAC 
value lower than 0.58 minus the overlap of standard deviations 
from both sides (with vs. without reversal) resulting in a value of 
0.2 would permit to assume a rocuronium dosing pattern that 
can be considered safe for the termination of anaesthesia wit-
hout reversal (which obviously be confirmed using relaxometry). 
This value individually occurred in only one case from 60 of the 
non-reversal patients.
Conclusion
Finally, we can conclude from our results that the clinically 
applied neuromuscular relaxation patterns do not show a suf-
ficiently clear difference in relation to the applied method of 
reversal or whether a reversal agent has been applied or not. 
In simple terms, we can summarise that it is impossible to 
estimate the need for the reversal of neuromuscular relaxation 
from the applied rocuronium dosing pattern. This inter-indi-
vidual variation seen as an overlap of dosing patterns reflects 
the unpredictability of spontaneous recovery times of neuro-
muscular relaxants and underscores the necessity of objective 
monitoring.
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Figure 1. Residual drug activity coefficient in the three study groups 
(mean±SD). The grey zone indicates the overlap zone of 1 SD, whi-
ch means that one cannot safely distinguish the necessity for reversal 
from the administered rocuronium dosage pattern
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